Tocilizumab-Induced Psoriasiform Rash in Rheumatoid Arthritis
| Autor: | Juan Antonio Sánchez Gaviño, Natalia Palmou-Fontana, E.M. Garcia-Martinez, Dennis McGonagle, Luis Iñiguez de Onzoño Martín |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Palmoplantar pustulosis Arthritis Dermatology Antibodies Monoclonal Humanized Arthritis Rheumatoid chemistry.chemical_compound Tocilizumab Psoriasis medicine Humans Rheumatoid factor skin and connective tissue diseases Aged biology business.industry Anti–citrullinated protein antibody medicine.disease Rash chemistry Antirheumatic Agents Rheumatoid arthritis biology.protein Female Drug Eruptions medicine.symptom business |
| Zdroj: | Dermatology. 228:311-313 |
| ISSN: | 1421-9832 1018-8665 |
| DOI: | 10.1159/000362266 |
| Popis: | Tocilizumab (TCZ) is a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor and has been approved for the treatment of rheumatoid arthritis (RA) patients who have had an inadequate response to previous biological therapies. Psoriasiform skin lesions, especially palmoplantar pustulosis lesions, are well described following anti-tumour necrosis factor therapy. We describe a 79-year-old woman with rheumatoid factor-positive, anti-citrullinated protein antibody-positive erosive RA, who developed a psoriasiform palmoplantar pustulosis reaction following treatment with TCZ therapy (IL-6 receptor). The rash showed histological features compatible with psoriasis and disappeared following discontinuation of TCZ. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|